Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study
Status:
Withdrawn
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Hypothesis:
A cluster of biochemical measurements (biomarkers) predict which diabetic patients will
respond to treatment with a therapeutic dose of rosiglitazone over a 12 week treatment
period.
Brief Summary:
The purpose of this study is to assess the predictive value of the biomarkers in diabetic
patients treated with a full dose of a thiazolidinedione (eg 4mg bid rosiglitazone) for 12
weeks.
Specifically - the questions asked are:
1. Do baseline measurements of a selected panel of biomarkers predict the patients'
response to rosiglitazone over 12 weeks?
2. How does the panel of biomarkers change over that 12 week treatment period?